183 completed, 60 terminated, 20 unknown, 11 withdrawn. 159 Phase 2, 87 Phase 1, 39 Phase 3, 5 Early Phase 1, 5 Not applicable.
Follow Lapatinib: new trials by email Literature Review of Lapatinib trials Research Report on Lapatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients GW572016 - Breast Cancer | Phase 1 / Phase 2 | Withdrawn | University of New Mexico | 2023-07-31 | 2023-08-14 | |
| Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer Trastuzumab (Single-Agent Anti-HER2 Therapy), Combination Anti-HER2 Therapy (Trastuzumab + Pertuzumab or Lapatinib) - Breast Neoplasms, Oncology | Completed | Deraya University | 80 | 2023-06-10 | 2026-02-18 | |
| Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer Lapatinib and Paclitaxel - Ovarian Cancer | Phase 1 | Completed | Frederick R. Ueland, M.D. | 16 | 2021-03-17 | 2025-06-29 |
| Antineoplastic Drugs in Elderly Patients Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs) - Cancer | Recruiting | Shandong University | 500 | 2021-01-01 | 2022-07-20 | |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy Erlotinib, Trastuzumab, Trastuzumab emtansine - Breast Cancer, Gastrointestinal Cancer | Phase 2 | Unknown | Fondazione per la Medicina Personalizzata | 400 | 2020-10-07 | 2023-10-03 |
| Molecular Profiling of Advanced Soft-tissue Sarcomas Nilotinib, Ceritinib, Capmatinib - Soft Tissue Sarcoma | Phase 3 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 603 | 2019-10-19 | 2026-04-29 |
| DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] Trastuzumab deruxtecan, Capecitabine, Lapatinib - Breast Cancer | Phase 3 | Completed | Daiichi Sankyo | 608 | 2018-08-01 | 2026-02-27 |
| The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer BAT8001 for injection, Lapatinib, Capecitabine - HER2-positive Advanced Breast Cancer | Phase 3 | Unknown | Bio-Thera Solutions | 410 | 2018-07-01 | 2019-12-04 |
| A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases RC48-ADC, Lapatinib, Capecitabine - Breast Neoplasms, Breast Diseases | Phase 2 / Phase 3 | Unknown | RemeGen Co., Ltd. | 301 | 2018-04-24 | 2024-02-20 |
| SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (vic-)trastuzumab duocarmazine, Physician's choice - Metastatic Breast Cancer | Phase 3 | Completed | Byondis B.V. | 437 | 2017-12-15 | 2023-10-19 |
| Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE) Pyrotinib Plus Capecitabine, Lapatinib Plus Capecitabine - HER2 Positive Metastatic Breast Cancer | Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 240 | 2017-05-03 | 2020-06-18 |
| Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Trastuzumab Emtansine, Lapatinib, Capecitabine - Breast Cancer | Phase 3 | Completed | Hoffmann-La Roche | 351 | 2017-04-24 | 2023-05-06 |
| A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin lapatinib/herceptin - HER2-positive Breast Cancer | Phase 2 / Phase 3 | Unknown | Peking Union Medical College Hospital | 482 | 2017-03-01 | 2017-07-28 |
| Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma Laboratory Biomarker Analysis, Lapatinib, Lapatinib Ditosylate - Anaplastic Astrocytoma, Anaplastic Ependymoma | Phase 1 | Completed | National Cancer Institute (NCI) | 29 | 2016-11-07 | 2024-11-06 |
| Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma biological test, GEMOX, Cetuximab - Cholangiocarcinoma of the Extrahepatic Bile Duct, Gallbladder Cancer | Phase 2 | Unknown | Shanghai Jiao Tong University School of Medicine | 152 | 2016-07-01 | 2018-05-07 |
| Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer Lapatinib, Trastuzumab, Paclitaxel - Neoplasms, Breast | Phase 2 | Unknown | Xijing Hospital | 100 | 2016-07-01 | 2017-09-06 |
| Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases Lapatinib in Tandem With Capecitabine - Metastatic Breast Cancer, Central Nervous System (CNS) Metastases | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 11 | 2016-01-06 | 2021-01-26 |
| Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease JTZ-951, Lapatinib - Anemia of Chronic Kidney Disease | Phase 1 | Completed | Akros Pharma Inc. | 10 | 2015-10-01 | 2016-04-28 |
| A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab pyrotinib, Lapatinib, capecitabine - HER2 Positive Metastatic Breast Cancer | Phase 1 / Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 128 | 2015-05-01 | 2018-07-09 |
| A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer lapatinib and capecitabine or vinorelbine - HER2 Positive Breast Cancer | Phase 2 | Completed | Sun Yat-sen University | 159 | 2015-01-09 | 2020-07-15 |
Showing 20 of 280. Sign in to see all of them.
Breast Neoplasms (167) · Neoplasms (30) · Neoplasm Metastasis (29) · Brain Neoplasms (16) · Breast Neoplasms, Male (15) · Head and Neck Neoplasms (8) · Stomach Neoplasms (7) · Urinary Bladder Neoplasms (7) · Colorectal Neoplasms (6) · Ovarian Neoplasms (6) · Squamous Cell Carcinoma of Head and Neck (6) · Carcinoma, Non-Small-Cell Lung (5) · Glioblastoma (5) · Inflammatory Breast Neoplasms (5) · Prostatic Neoplasms (5)
GlaxoSmithKline (57) · National Cancer Institute (NCI) (29) · Novartis Pharmaceuticals (20) · M.D. Anderson Cancer Center (6) · Cancer Trials Ireland (5) · European Organisation for Research and Treatment of Cancer - EORTC (5) · UNC Lineberger Comprehensive Cancer Center (5) · Memorial Sloan Kettering Cancer Center (4) · Baylor Breast Care Center (3) · Case Comprehensive Cancer Center (3) · GBG Forschungs GmbH (3) · Georgetown University (3) · Jonsson Comprehensive Cancer Center (3) · Mayo Clinic (3) · SCRI Development Innovations, LLC (3)
United States (169) · France (38) · Italy (38) · Canada (37) · Germany (34) · Spain (34) · United Kingdom (32) · South Korea (29) · Belgium (23) · Russia (21) · China (20) · Poland (20) · Peru (18) · Greece (17) · Israel (17)
Mothaffar Rimawi, MD (3) · Edith A. Perez, MD (2) · Helen K. Chew, MD (2) · Jenny C Chang, MD (2) · Mark M. Moasser, MD (2) · Nancy Lin, MD (2) · Pierre Fumoleau, MD, PhD (2) · Sabino De Placido, MD (2) · Agustin Garcia (1) · Ahmad Awada, MD, PhD (1) · Ajjai S. Alva, M.D. (1)
PMID 23054212, PMID 23234763, PMID 36135045, PMID 39613746, PMID 18188694, PMID 18692224, PMID 19394894, PMID 19706807, PMID 19737952, PMID 20030854, PMID 20095796, PMID 20179708, PMID 20214527, PMID 20479410, PMID 20606083, PMID 20736298, PMID 20857170, PMID 21359953, PMID 21609937, PMID 21676217, PMID 21784672, PMID 21989330, PMID 22084371, PMID 22257523, PMID 22257673, PMID 22276820, PMID 22325452, PMID 22437872, PMID 22476856, PMID 22785351, PMID 22839200, PMID 22989664, PMID 22999386, PMID 23020162, PMID 23108952, PMID 23122784, PMID 23146956, PMID 23509322, PMID 23569315, PMID 23667487, PMID 23676418, PMID 23878115, PMID 23953056, PMID 24013510, PMID 24057042, PMID 24158411, PMID 24252402, PMID 24304724, PMID 24346280, PMID 24395109
2009 (6), 2005 (5), N01CM62201 (4), P30CA015083 (3), U10CA180821 (3), 2008 (2), 2018 (2), N01CM62203 (2), N01CM62209 (2), P30CA008748 (2), P30CA016672 (2), P30CA022453 (2), P30CA043703 (2), P30CA093373 (2), U01CA062487 (2)